Sino BiologicalAntibody-Drug Conjugates (ADCs) have been transformative in oncology, offering targeted cancer treatments that enhance efficacy while sparing healthy cells. However, the potential of ADCs extends well beyond cancer care. From autoimmune diseases to metabolic disorders, advancements in ADC technology are paving the way for breakthroughs across a range of therapeutic areas. This article explores how ADCs are redefining treatment paradigms and improving patient outcomes in diverse fields of medicine.
GettyImagesExplore the evolving world of GLP-1 receptor agonists in Issue 42 of The Altascientist, featuring insights on their expanding applications, early-phase development, and real-world case studies.
3PBIOVIAN, a leading Contract Development and Manufacturing Organization (CDMO) with locations in Pamplona (Spain) and Turku (Finland), has been awarded the prestigious CDMO Leadership Award 2025 in the “Cell & Gene Therapy International” category. This award recognizes the excellence of the services that 3PBIOVIAN provides to the Advanced Therapies industry, solidifying its position as a leader in the international sector.
Eleva GmbHFreiburg-based Eleva relies on its moss-based platform for the development of new biologics both independently and with partners. A new alliance with Spanish CDMO 3PBIOVIAN now secures clinical production capacity for both activities.
TriLink BiotechnologiesThrough a new partnership with VWR, TriLink Biotechnologies has made its catalogue of industry-leading nucleic acid technologies more available in Europe. By improving the ordering process and reducing lead times, this partnership will support early-phase researchers and established commercial clients with cutting-edge mRNA products.
Technologiepark HeidelbergThe Technologiepark Heidelberg has been shaping Heidelberg‘s startup ecosystem with 100,000 sqm of lab and office spaces, individual startup support, and top events for over 40 years – offering ideal conditions for established companys and startups in the fields of life sciences, biotech, industry tech, and AI.
Sino BiologicalHigh-Quality HIV Antigens for Cutting-Edge Solutions
Customized Enzymes and Reagents from New England Biolabs
Neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) suffer from a scarcity of effective treatments. Current therapies primarily provide symptomatic relief but do not address the underlying pathology, failing to slow or halt disease progression. This underscores the urgent need to identify new therapeutic targets relevant to the pathology of these conditions. Kinases represent highly tractable drug targets, with kinase inhibitors achieving significant success, particularly in oncology. However, their potential in neurodegenerative diseases remains largely unexplored, presenting a promising avenue for future research and therapeutic development.
Kerttu Penttilä PhotographyMedix Biochemica expands its offering of critical in vitro diagnostics (IVD) raw materials to premium blockers and stabilizers by acquiring CANDOR Bioscience.